Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Benzer Materyaller

• Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
  Yazar:: Jasielec, Jagoda K., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
  Yazar:: Dytfeld, Dominik, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
  Yazar:: Dimopoulos, M A, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
  Yazar:: Jakubowiak, Andrzej J., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
  Yazar:: Mele, Giuseppe, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)